{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:10:18Z","timestamp":1722532218990},"reference-count":75,"publisher":"Akademiai Kiado Zrt.","issue":"36","license":[{"start":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T00:00:00Z","timestamp":1694304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,9,10]]},"abstract":"<jats:p>Az osteoporosis a civiliz\u00e1lt vil\u00e1gban az \u00f6tven \u00e9vesn\u00e9l id\u0151sebb koroszt\u00e1lyban az\n                    egyik leggyakoribb, az \u00e9letmin\u0151s\u00e9get s\u00falyosan ront\u00f3 \u00e1llapot. A csontt\u00f6megveszt\u00e9s\n                    megel\u0151z\u00e9s\u00e9ben \u00e9s kezel\u00e9s\u00e9ben ma a legelterjedtebb az antireszorpt\u00edv gy\u00f3gyszerek\n                    alkalmaz\u00e1sa, amelyek az osteoclastok blokkol\u00e1sa r\u00e9v\u00e9n lass\u00edtj\u00e1k a csontt\u00f6meg\n                    veszt\u00e9s\u00e9t. Az antireszorpt\u00edv kezel\u00e9s egyik, b\u00e1r nem gyakori vezet\u0151 mell\u00e9khat\u00e1sa\n                    az invaz\u00edv sz\u00e1jseb\u00e9szeti beavatkoz\u00e1sok ut\u00e1n el\u0151fordul\u00f3 csontnekr\u00f3zis, amely\n                    \u201emedication-related osteonecrosis of the jaw (MRONJ)\u201d n\u00e9ven szerepel az\n                    angolsz\u00e1sz irodalomban. Az osteoporosis kezel\u00e9s\u00e9ben az ut\u00f3bbi k\u00e9t \u00e9vtizedben\n                    fokozatosan egyre nagyobb teret k\u00f6vetelnek maguknak az anabolikus\n                    hormonk\u00e9sz\u00edtm\u00e9nyek, els\u0151sorban a rekombin\u00e1ns hum\u00e1n parathormon (1\u201334)\n                    alkalmaz\u00e1sa. E hormonk\u00e9sz\u00edtm\u00e9ny teriparatid n\u00e9ven m\u00e1r t\u00f6bb mint k\u00e9t \u00e9vtizede van\n                    klinikai alkalmaz\u00e1sban. Egyes k\u00f6zlem\u00e9nyek szerint a teriparatid hat\u00e1sosabb a\n                    csonts\u0171r\u0171s\u00e9g megtart\u00e1s\u00e1ban \u00e9s a patol\u00f3gi\u00e1s csontt\u00f6r\u00e9sek kezel\u00e9s\u00e9ben, mint az\n                    antireszorpt\u00edv gy\u00f3gyszerek. Igazolt, hogy a napi egyszeri d\u00f3zisban adott\n                    parathormon fokozza az \u00f6sszehangolt csont\u00e1t\u00e9p\u00fcl\u00e9st, \u00e9s a folyamatot a\n                    csontk\u00e9pz\u00e9s ir\u00e1ny\u00e1ba tolja el. Sz\u00e1mos \u00e1llatk\u00eds\u00e9rlet \u00e9s hum\u00e1n klinikai\n                    vizsg\u00e1latok igazolt\u00e1k, hogy a sziszt\u00e9m\u00e1san, napi egyszeri d\u00f3zisban adott\n                    teriparatid gyors\u00edtotta a callusk\u00e9pz\u0151d\u00e9st, ler\u00f6vid\u00edtette a gy\u00f3gyul\u00e1si id\u0151t, \u00e9s\n                    egyben javultak a csont mechanikai tulajdons\u00e1gai is. A parathormon \u00fan.\n                    \u201eoff-label\u201d indik\u00e1ci\u00f3ja azonban m\u00e9g mindig nem megalapozott. Ugyanakkor egyre\n                    t\u00f6bb olyan adat gy\u0171lt \u00f6ssze a nemzetk\u00f6zi irodalomban, miszerint a teriparatid\n                    hat\u00e1sos az egy\u00e9bk\u00e9nt hagyom\u00e1nyos kezel\u00e9sre rezisztens, gy\u00f3gyszer okozta\n                    \u00e1llcsontnekr\u00f3zis gy\u00f3gy\u00edt\u00e1s\u00e1ban is. A k\u00f6zlem\u00e9ny c\u00e9lja \u00f6sszefoglalni a parathormon\n                    anabolikus farmakol\u00f3giai hat\u00e1s\u00e1val kapcsolatos irodalmat \u00e9s az elm\u00falt \u00e9vtizedben\n                    az irodalomban k\u00f6z\u00f6lt eredm\u00e9nyek alapj\u00e1n a parathormon alkalmaz\u00e1s\u00e1val az\n                    antireszorpt\u00edv gy\u00f3gyszerek okozta \u00e1llcsontnekr\u00f3zisok ter\u00e1pi\u00e1j\u00e1ban el\u00e9rt\n                    eredm\u00e9nyeket. Az elm\u00falt 15 \u00e9vben megjelent nagysz\u00e1m\u00fa esetk\u00f6zlem\u00e9ny \u00e9s a limit\u00e1lt\n                    sz\u00e1m\u00fa klinikai vizsg\u00e1lat eredm\u00e9nyei alapj\u00e1n felt\u00e9telezhet\u0151, hogy a\n                    teriparatidk\u00e9sz\u00edtm\u00e9nyeket alkalmazni lehetne a hagyom\u00e1nyos kezel\u00e9sre rezisztens\n                    \u00e1llcsontnekr\u00f3zisok kezel\u00e9s\u00e9ben is. \u00c1m m\u00e9g tov\u00e1bbi randomiz\u00e1lt, kontroll\u00e1lt\n                    klinikai vizsg\u00e1latokra van sz\u00fcks\u00e9g ahhoz, hogy kimondhat\u00f3 legyen: a teriparatid\n                    val\u00f3ban hat\u00e9kony \u00e9s biztons\u00e1gos kezel\u00e9si alternat\u00edva lenne a hagyom\u00e1nyos\n                    kezel\u00e9sre nem reag\u00e1l\u00f3, gy\u00f3gyszer okozta \u00e1llcsontnekr\u00f3zis-esetek kezel\u00e9s\u00e9ben. Orv\n                    Hetil. 2023; 164(36): 1406\u20131415.<\/jats:p>","DOI":"10.1556\/650.2023.32861","type":"journal-article","created":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T14:40:41Z","timestamp":1694356841000},"page":"1406-1415","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":3,"title":["Hum\u00e1n rekombin\u00e1ns parathormon (teriparatid) mint alternat\u00edv megold\u00e1s a gy\u00f3gyszer okozta \u00e1llcsontnekr\u00f3zis ter\u00e1pi\u00e1j\u00e1ra"],"prefix":"10.1556","volume":"164","author":[{"given":"Istv\u00e1n","family":"Gera","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, Fogorvostudom\u00e1nyi Kar, Parodontol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 47., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolette","family":"Sz\u00fccs","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","unstructured":"1. Hernlund E, Svedbom A, Iverg\u00e5rd M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8: 136.","journal-title":"Arch Osteoporos"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30: 3-44. Erratum: Osteoporos Int. 2020; 31: 209. Erratum: Osteoporos Int. 2020; 31: 801.","DOI":"10.1007\/s00198-020-05303-5"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management","volume":"102","author":"Ruggiero","year":"2006","unstructured":"3. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102: 433-441.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Szentp\u00e9teri S, Rest\u00e1r L, N\u00e9meth Z, et al. Prognostic factors of the medication-related osteonecrosis of the jaw. [A gy\u00f3gyszer okozta \u00e1llcsontnekr\u00f3zis progn\u00f3zis\u00e1t befoly\u00e1sol\u00f3 faktorok.] Orv Hetil. 2020; 161: 283-289. [Hungarian].","DOI":"10.1556\/650.2019.31621"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/odi.12632","article-title":"Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study","volume":"23","author":"Fung","year":"2017","unstructured":"5. Fung P, Bedogni G, Bedogni A, et al. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis. 2017; 23: 477-483.","journal-title":"Oral Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s11999-010-1722-9","article-title":"Anabolic agents and bone quality","volume":"469","author":"Sibai","year":"2011","unstructured":"6. Sibai T, Morgan EF, Einhorn TA, et al. Anabolic agents and bone quality. Clin Orthop Relat Res. 2011; 469: 2215-2224.","journal-title":"Clin Orthop Relat Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.tripleo.2011.04.020","article-title":"A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution","volume":"112","author":"Subramanian","year":"2011","unstructured":"7. Subramanian G, Cohen HV, Quek SY. A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 112: 744-753.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1742-1241.2003.tb10593.x","article-title":"Teriparatide (rhPTH 1-34) for the treatment of osteoporosis","volume":"57","author":"PR","year":"2003","unstructured":"8. Ebeling PR, Russell RG. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. Int J Clin Pract. 2003; 57: 710-718.","journal-title":"Int J Clin Pract"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Potts JT Jr. Chemistry and physiology of parathyroid hormone. Clin Endocrinol (Oxf). 1976; 5(Suppl): 307S-315S.","DOI":"10.1111\/j.1365-2265.1976.tb03839.x"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1210\/endo-16-5-547","article-title":"On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol","volume":"16","author":"Selye","year":"1932","unstructured":"10. Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932; 16: 547-558.","journal-title":"Endocrinology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1113\/jphysiol.1933.sp003032","article-title":"The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat","volume":"79","author":"LI","year":"1933","unstructured":"11. Pugsley LI, Selye H. The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat. J Physiol (Lond). 1933; 79: 113-117.","journal-title":"J Physiol (Lond)"},{"key":"ref11","unstructured":"12. Hock JM. Anabolic actions of PTH in the skeletons of animals. J Musculoskelet Neuronal Interact. 2001; 2: 33-47."},{"key":"ref12","unstructured":"13. Gera I, Dobrolet N, Hock JM. Intermittent but not continuous PTH (hPTH-1-34) increases bone mass independently of resorption. J Bone Miner Res. 1989; 4(Suppl 1): S744."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/BF02556716","article-title":"Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3","volume":"38","author":"Gunness-Hey","year":"1986","unstructured":"14. Gunness-Hey M, Hock JM, Gera I, et al. Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3. Calcif Tissue Int. 1986; 38: 234-238.","journal-title":"Calcif Tissue Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/BF02556637","article-title":"1,25 dihydroxyvitamin D3 alone or in combination with parathyroid hormone does not increase bone mass in young rats","volume":"43","author":"Gunness-Hey","year":"1988","unstructured":"15. Gunness-Hey M, Gera I, Fonseca J, et al. 1,25 dihydroxyvitamin D3 alone or in combination with parathyroid hormone does not increase bone mass in young rats. Calcif Tissue Int. 1988; 43: 284-288.","journal-title":"Calcif Tissue Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF02556623","article-title":"Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats","volume":"40","author":"Gera","year":"1987","unstructured":"16. Gera I, Hock JM, Gunness-Hey M, et al. Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats. Calcif Tissue Int. 1987; 40: 206- 211.","journal-title":"Calcif Tissue Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1210\/endo-122-6-2899","article-title":"Human parathyroid hormone (1-34) increases bone mass in ovariectomized and orchidectomized rats","volume":"122","author":"Hock","year":"1988","unstructured":"17. Hock JM, Gera I, Fonseca J, et al. Human parathyroid hormone (1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 1988; 122: 2899-2904.","journal-title":"Endocrinology"},{"key":"ref17","unstructured":"18. Steen-Hacket L, Gera I, Fonseca J, et al. Human parathyroid hormone 1-34 increases bone mass in denervated legs of rats. J Bone Miner Res. 1987; 2(Suppl): 57."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jbmr.5650040321","article-title":"Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo","volume":"4","author":"Hock","year":"1989","unstructured":"19. Hock JM, Hummert JR, Boyce R, et al. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J Bone Miner Res. 1989; 4: 449-458.","journal-title":"J Bone Miner Res"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Hock JM, Gera I. Effects of continuous and intermittent administration and of inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 1992; 7: 65-72.","DOI":"10.1002\/jbmr.5650070110"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","unstructured":"21. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104: 439-446.","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S8756-3282(97)00198-1","article-title":"Effects of intermittent administration of low dose human PTH (1-34) on cancellous and cortical bone of lumbar vertebral bodies in adult beagles","volume":"21","author":"Zhang","year":"1997","unstructured":"22. Zhang L, Takahashi HE, Inoue J, et al. Effects of intermittent administration of low dose human PTH (1-34) on cancellous and cortical bone of lumbar vertebral bodies in adult beagles. Bone 1997; 21: 501-506.","journal-title":"Bone"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Brommage R, Hotchkiss CE, Lees CJ, et al. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab. 1999; 84: 3757-3763.","DOI":"10.1210\/jcem.84.10.6039"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S8756-3282(00)00430-0","article-title":"Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)","volume":"28","author":"Jerome","year":"2001","unstructured":"24. Jerome CP, Burr DB, van Bibber T, et al. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001; 28: 150-159.","journal-title":"Bone"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Jerome CP, Johnson CS, Lees CJ. Effect of treatment for 3 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1995; 17(4 Suppl): 415S-420S.","DOI":"10.1016\/8756-3282(95)00320-D"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","article-title":"Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys","volume":"16","author":"Burr","year":"2001","unstructured":"26. Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001; 16: 157-165.","journal-title":"J Bone Miner Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/019262339802600318","article-title":"Spontaneous neoplasm incidences in Fisher 344 rats and B6C3F1 mice in two-year carcinogenicity studies: a National Toxicology Program update","volume":"26","author":"Haseman","year":"1998","unstructured":"27. Haseman J, Hailey JR, Morris RW. Spontaneous neoplasm incidences in Fisher 344 rats and B6C3F1 mice in two-year carcinogenicity studies: a National Toxicology Program update. Toxicol Pathol. 1998; 26: 428-441.","journal-title":"Toxicol Pathol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1359\/JBMR.051023","article-title":"5 years of experience on the use and safety of the drug for the treatment of osteoporosis","volume":"21","author":"AH Jr","year":"2006","unstructured":"28. Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006; 21: 354-365.","journal-title":"J Bone Miner Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial","volume":"15","author":"Lane","year":"2000","unstructured":"29. Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000; 15: 944-951.","journal-title":"J Bone Miner Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","unstructured":"30. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16: 925-931.","journal-title":"J Bone Miner Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s007740170048","article-title":"Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur","volume":"19","author":"Reeve","year":"2001","unstructured":"31. Reeve J, Mitchell A, Tellez M, et al. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab. 2001; 19: 102-114.","journal-title":"J Bone Miner Metab"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","unstructured":"32. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1210\/jc.82.2.620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","unstructured":"33. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 1997; 82: 620-628.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0149-2918(04)90128-2","article-title":"Teriparatide: a review","volume":"26","author":"Quattrocchi","year":"2004","unstructured":"34. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther. 2004; 26: 841-854.","journal-title":"Clin Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"SL","year":"2012","unstructured":"35. Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012; 66: 199-209.","journal-title":"Int J Clin Pract"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"D\u00edez-P\u00e9rez","year":"2019","unstructured":"36. D\u00edez-P\u00e9rez A, Marin F, Eriksen EF, et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 2019; 120: 1-8.","journal-title":"Bone"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","unstructured":"37. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146: 326-339.","journal-title":"Ann Intern Med"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Wang YK, Qin SQ, Ma T, et al. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017; 96: e6970.","DOI":"10.1097\/MD.0000000000006970"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","unstructured":"39. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60: 3346-3355.","journal-title":"Arthritis Rheum"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2106\/JBJS.H.01030","article-title":"Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis: results from two randomized controlled trials","volume":"91","author":"Bouxsein","year":"2009","unstructured":"40. Bouxsein ML, Chen P, Glass EV, et al. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis: results from two randomized controlled trials. J Bone Joint Surg Am. 2009; 91: 1329-1338.","journal-title":"J Bone Joint Surg Am"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Shen L, Xie X, Su Y, et al. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a metaanalysis of randomized controlled trials. PloS ONE 2011; 6: e26267.","DOI":"10.1371\/journal.pone.0026267"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","unstructured":"42. Geusens P, Marin F, Kendler DL, et al. Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res. 2018; 33: 783-794.","journal-title":"J Bone Miner Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1359\/jbmr.090527","article-title":"Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate","volume":"24","author":"Dobnig","year":"2009","unstructured":"43. Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2009; 24: 1998-2006.","journal-title":"J Bone Miner Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.12659\/MSM.892581","article-title":"Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs","volume":"20","author":"Song","year":"2014","unstructured":"44. Song J, Jin Z, Chang F, et al. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs. Med Sci Monit. 2014; 20: 2624-2632.","journal-title":"Med Sci Monit"},{"issue":"9886","key":"ref44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","unstructured":"45. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013; 382(9886): 50-56.","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","article-title":"Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial","volume":"7","author":"Tsai","year":"2019","unstructured":"46. Tsai JN, Lee H, David NL, et al. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019; 7: 767-775.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches","volume":"139","author":"Langdahl","year":"2020","unstructured":"47. Langdahl B. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 2020; 139: 115516.","journal-title":"Bone"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1359\/jbmr.2002.17.11.2038","article-title":"Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34)","volume":"17","author":"Nakajima","year":"2002","unstructured":"48. Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res. 2002; 17: 2038-2047.","journal-title":"J Bone Miner Res"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49. Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (1-34; teriparatide) enhances experimental fracture healing. J Bone Joint Surg Am. 2005; 87: 731-741.","DOI":"10.2106\/JBJS.D.02115"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1359\/jbmr.090731","article-title":"Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures","volume":"25","author":"Aspenberg","year":"2010","unstructured":"50. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25: 404-414.","journal-title":"J Bone Miner Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s11999-015-4669-z","article-title":"Does teriparatide improve femoral neck fracture healing: results from a randomized placebo-controlled trial","volume":"474","author":"Bhandari","year":"2016","unstructured":"51. Bhandari M, Jin L, See K, et al. Does teriparatide improve femoral neck fracture healing: results from a randomized placebo-controlled trial. Clin Orthop Relat Res. 2016; 474: 1234-1244.","journal-title":"Clin Orthop Relat Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1517\/14712598.2015.977249","article-title":"The effect of parathyroid hormone and teriparatide on fracture healing","volume":"15","author":"Campbell","year":"2015","unstructured":"52. Campbell EJ, Campbell GM, Hanley DA. The effect of parathyroid hormone and teriparatide on fracture healing. Expert Opin Biol Ther. 2015; 15: 119-129.","journal-title":"Expert Opin Biol Ther"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53. Collinge C, Juan Favela J. Use of teriparatide in osteoporotic fracture patients. Injury 2016; 47(Suppl 1): S36-S38.","DOI":"10.1016\/S0020-1383(16)30009-2"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"6040379","DOI":"10.1155\/2016\/6040379","article-title":"The effect of teriparatide on fracture healing of osteoporotic patients: a meta-analysis of randomized controlled trials","volume":"2016","author":"Lou","year":"2016","unstructured":"54. Lou S, Lv H, Wang G, et al. The effect of teriparatide on fracture healing of osteoporotic patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2016; 2016: 6040379.","journal-title":"Biomed Res Int"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"55. Shi Z, Zhou H, Pan B, et.al. Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis. PLoS ONE 2016; 11(12): e0168691.","DOI":"10.1371\/journal.pone.0168691"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/odi.12333","article-title":"Management of bisphosphonate-related osteonecrosis of the jaw: a literature review","volume":"21","author":"Spanou","year":"2015","unstructured":"56. Spanou A, Lyritis GP, Chronopoulos E, et al. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review. Oral Dis. 2015; 21: 927-936.","journal-title":"Oral Dis"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0022034512464779","article-title":"Parathyroid hormone applications in the craniofacial skeleton","volume":"92","author":"HL","year":"2013","unstructured":"57. Chan HL, McCauley LK. Parathyroid hormone applications in the craniofacial skeleton. J Dent Res. 2013; 92: 18-25.","journal-title":"J Dent Res"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","volume":"363","author":"Bashutski","year":"2010","unstructured":"58. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010; 363: 2396-2405.","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1902\/cap.2012.110043","article-title":"Systemic teriparatide administration promotes osseous regeneration of an intrabony defect: a case report","volume":"2","author":"Bashutski","year":"2012","unstructured":"59. Bashutski JD, Kinney JS, Benavides E, et al. Systemic teriparatide administration promotes osseous regeneration of an intrabony defect: a case report. Clin Adv Periodontics 2012; 2: 66-71.","journal-title":"Clin Adv Periodontics"},{"key":"ref59","unstructured":"60. Grover HS, Luthra S, Maroo S. Teriparatide: a novel means to ultimately achieve true regeneration!!! J Clin Diag Res. 2013; 7: 1820-1823."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4062\/biomolther.2021.001","article-title":"Recent advances of therapeutic targets for the treatment of periodontal disease","volume":"29","author":"Kim","year":"2021","unstructured":"61. Kim WJ, Soh Y, Heo SM. Recent advances of therapeutic targets for the treatment of periodontal disease. Biomol Ther (Seoul). 2021; 29: 263-267.","journal-title":"Biomol Ther (Seoul)"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.ijom.2013.05.001","article-title":"The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study","volume":"42","author":"Dayisoylu","year":"2013","unstructured":"62. Dayisoylu EH, \u015eenel F\u00c7, \u00dcng\u00f6r C, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. Int J Oral Maxillofac Surg. 2013; 42: 1475-1480.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcms.2016.12.010","article-title":"Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: a randomized, controlled preclinical study in rats","volume":"45","author":"Zandi","year":"2017","unstructured":"63. Zandi M, Dehghan A, Mohammadi-Mofrad A, et al. Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: a randomized, controlled preclinical study in rats. J Craniomaxillofac Surg. 2017; 45: 275-280.","journal-title":"J Craniomaxillofac Surg"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.joms.2015.07.005","article-title":"Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study","volume":"74","author":"Keskinruzgar","year":"2016","unstructured":"64. Keskinruzgar A, Bozdag Z, Aras MH, et al. Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study. J Oral Maxillofac Surg. 2016; 74: 68-78.","journal-title":"J Oral Maxillofac Surg"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007; 65: 573-580. Erratum in: J Oral Maxillofac Surg. 2007; 65: 1059.","DOI":"10.1016\/j.joms.2006.10.076"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"66. Kwon YD, Kim DY. Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ). Dent J (Basel) 2016; 4: 41.","DOI":"10.3390\/dj4040041"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67. Chopra K, Malhan N. Teriparatide for the treatment of medication-related osteonecrosis of the jaw. Am J Ther. 2020; 28: e469-e477.","DOI":"10.1097\/MJT.0000000000001182"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00198-021-06078-z","article-title":"Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis","volume":"32","author":"Dos Santos Ferreira","year":"2021","unstructured":"68. Dos Santos Ferreira L, Abreu LG, Calderipe CB, et al. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis. Osteoporos Int. 2021; 32: 2449-2459.","journal-title":"Osteoporos Int"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00198-014-2622-8","article-title":"Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw","volume":"25","author":"Kim","year":"2014","unstructured":"69. Kim KM, Park W, Oh SY, et al. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int. 2014; 25: 1625-1632.","journal-title":"Osteoporos Int"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"70. Pelaz A, Junquera L, Gallego L, et al. Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide. Med Oral Patol Oral Cir Bucal. 2014; 19: e320-e326.","DOI":"10.4317\/medoral.19458"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/jbmr.3237","article-title":"Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study","volume":"32","author":"Jung","year":"2017","unstructured":"71. Jung J, Yoo HY, Kim GT, et al. Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study. J Bone Miner Res. 2017; 32: 2445-2452.","journal-title":"J Bone Miner Res"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","unstructured":"72. Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol. 2020; 38: 2971-2980.","journal-title":"J Clin Oncol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jos.2020.01.012","article-title":"Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): a multicenter retrospective analysis in Japan","volume":"25","author":"Morishita","year":"2020","unstructured":"73. Morishita K, Yamada SI, Kawakita A, et al. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): a multicenter retrospective analysis in Japan. J Orthop Sci. 2020; 25: 1079-1083.","journal-title":"J Orthop Sci"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/antiox10050680","article-title":"Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: a narrative review on new molecular and cellular therapeutic approaches","volume":"10","author":"SW","year":"2021","unstructured":"74. On SW, Cho SW, Byun SH, et al. Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: a narrative review on new molecular and cellular therapeutic approaches. Antioxidants (Basel) 2021; 10: 680.","journal-title":"Antioxidants (Basel)"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijom.2020.07.021","article-title":"The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw","volume":"50","author":"Anabtawi","year":"2021","unstructured":"75. Anabtawi M, Tweedale H, Mahmood H. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2021; 50: 501-510.","journal-title":"Int J Oral Maxillofac Surg"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/36\/article-p1406.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/36\/article-p1406.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/36\/article-p1406.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:10:17Z","timestamp":1697800217000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/36\/article-p1406.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,10]]},"references-count":75,"journal-issue":{"issue":"36"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32861","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,10]]}}}